|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cao W, Chen HD, Yu YW, Li N and Chen WQ:
Changing profiles of cancer burden worldwide and in China: A
secondary analysis of the global cancer statistics 2020. Chin Med J
(Engl). 134:783–791. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Whitson BA, Groth SS, Duval SJ, Swanson SJ
and Maddaus MA: Surgery for early-stage non-small cell lung cancer:
A systematic review of the video-assisted thoracoscopic surgery
versus thoracotomy approaches to lobectomy. Ann Thorac Surg.
86:2008–2018. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Horinouchi H, Atagi S, Oizumi S, Ohashi K,
Kato T, Kozuki T, Seike M, Sone T, Sobue T, Tokito T, et al:
Real-world outcomes of chemoradiotherapy for unresectable stage III
non-small cell lung cancer: The SOLUTION study. Cancer Med.
9:6597–6608. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tachihara M, Dokuni R, Okuno K, Tokunaga
S, Nakata K, Katsurada N, Yamamoto M, Nagano T, Kobayashi K, Tanaka
Y, et al: Phase II study of adjuvant chemotherapy with pemetrexed
and cisplatin with a short hydration method for completely resected
nonsquamous non-small cell lung cancer. Thorac Cancer.
11:2536–2541. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Delaney GP and Barton MB: Evidence-based
estimates of the demand for radiotherapy. Clin Oncol (R Coll
Radiol). 27:70–76. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garg A, Batra U, Choudhary P, Jain D,
Khurana S, Malik PS, Muthu V, Prasad KT, Singh N, Suri T and Mohan
A: Clinical predictors of response to EGFR-tyrosine kinase
inhibitors in EGFR-mutated non-small cell lung cancer: A real-world
multicentric cohort analysis from India. Curr Probl Cancer.
44:1005702020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu C, Yu H, Chang J, Chen H, Li Y, Zhao
W, Zhao K, Zhu Z, Sun S, Fan M and Wang J: Crizotinib in Chinese
patients with ROS1-rearranged advanced non-small-cell lung cancer
in routine clinical practice. Target Oncol. 14:315–323. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Zeng L, Zhou C, Li Y, Wu L, Xia
C, Jiang W, Hu Y, Liao D, Xiao L, et al: Detection of
nonreciprocal/reciprocal ALK translocation as poor predictive
marker in patients with first-line crizotinib-treated
ALK-rearranged NSCLC. J Thorac Oncol. 15:1027–1036. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bylicki O, Paleiron N, Margery J, Guisier
F, Vergnenegre A, Robinet G, Auliac JB, Gervais R and Chouaid C:
Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or
ALK-translocated non-small-cell lung cancer. Target Oncol.
12:563–569. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Balata H, Fong KM, Hendriks LE, Lam S,
Ostroff JS, Peled N, Wu N and Aggarwal C: Prevention and early
detection for NSCLC: Advances in thoracic oncology 2018. J Thorac
Oncol. 14:1513–1527. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang SR, Schultheis AM, Yu H, Mandelker D,
Ladanyi M and Büttner R: Precision medicine in non-small cell lung
cancer: Current applications and future directions. Semin Cancer
Biol. Jul 27–2020.(Epub ahead of print). doi:
10.1016/j.semcancer.2020.07.009. View Article : Google Scholar
|
|
14
|
Imakita T, Matsumoto H, Hirano K, Morisawa
T, Sakurai A and Kataoka Y: Impact on prognosis of rebiopsy in
advanced non-small cell lung cancer patients after epidermal growth
factor receptor-tyrosine kinase inhibitor treatment: A systematic
review. BMC Cancer. 19:1052019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hsu PC, Tian B, Yang YL, Wang YC, Liu S,
Urisman A, Yang CT, Xu Z, Jablons DM and You L: Cucurbitacin E
inhibits the Yes-associated protein signaling pathway and
suppresses brain metastasis of human non-small cell lung cancer in
a murine model. Oncol Rep. 42:697–707. 2019.PubMed/NCBI
|
|
16
|
Rao J, Wu X, Zhou X, Deng R and Ma Y:
TMEM205 is an independent prognostic factor and is associated with
immune cell infiltrates in hepatocellular carcinoma. Front Genet.
11:5757762020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schmit K and Michiels C: TMEM proteins in
cancer: A review. Front Pharmacol. 9:13452018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Marx S, Dal Maso T, Chen JW, Bury M,
Wouters J, Michiels C and Le Calvé B: Transmembrane (TMEM) protein
family members: Poorly characterized even if essential for the
metastatic process. Semin Cancer Biol. 60:96–106. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fujitomo T, Daigo Y, Matsuda K, Ueda K and
Nakamura Y: Critical function for nuclear envelope protein TMEM209
in human pulmonary carcinogenesis. Cancer Res. 72:4110–4118. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang X, Yu X, Jiang G, Miao Y, Wang L,
Zhang Y, Liu Y, Fan C, Lin X, Dong Q, et al: Cytosolic TMEM88
promotes invasion and metastasis in lung cancer cells by binding
DVLS. Cancer Res. 75:4527–4537. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ma R, Feng N, Yu X, Lin H, Zhang X, Shi O,
Zhang H, Zhang S, Li L, Zheng M, et al: Promoter methylation of
Wnt/β-Catenin signal inhibitor TMEM88 is associated with
unfavorable prognosis of non-small cell lung cancer. Cancer Biol
Med. 14:377–386. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu J and Zhu H: TMEM106A inhibits cell
proliferation, migration, and induces apoptosis of lung cancer
cells. J Cell Biochem. Nov 19–2018.(Epub ahead of print). doi:
10.1002/jcb.28057.
|
|
23
|
Zhang X, Zhang Y, Miao Y, Zhou H, Jiang G
and Wang E: TMEM17 depresses invasion and metastasis in lung cancer
cells via ERK signaling pathway. Oncotarget. 8:70685–70694. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao Y, Song K, Zhang Y, Xu H, Zhang X,
Wang L, Fan C, Jiang G and Wang E: TMEM17 promotes malignant
progression of breast cancer via AKT/GSK3β signaling. Cancer Manag
Res. 10:2419–2428. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Park S, Kim M, Hong Y, Lee H, Tran Q, Kim
C, Kwon SH, Park J, Park J and Kim SH: Myristoylated TMEM39AS41, a
cell-permeable peptide, causes lung cancer cell death. Toxicol Res.
36:123–130. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Asamura H, Chansky K, Crowley J, Goldstraw
P, Rusch VW, Vansteenkiste JF, Watanabe H, Wu YL, Zielinski M, Ball
D, et al: The international association for the study of lung
cancer lung cancer staging project: Proposals for the revision of
the N descriptors in the forthcoming 8th edition of the TNM
classification for lung cancer. J Thorac Oncol. 10:1675–1684. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eberhardt WE, Mitchell A, Crowley J, Kondo
H, Kim YT, Turrisi A III, Goldstraw P, Rami-Porta R; International
Association for Study of Lung Cancer Staging, ; Prognostic Factors
Committee, Advisory Board Members and Participating Institutions:
The IASLC lung cancer staging project: Proposals for the revision
of the M descriptors in the forthcoming eighth edition of the TNM
classification of lung cancer. J Thorac Oncol. 10:1515–1522. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nagy Á, Munkácsy G and Győrffy B:
Pancancer survival analysis of cancer hallmark genes. Sci Rep.
11:60472021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar
|
|
30
|
Raponi M, Zhang Y, Yu J, Chen G, Lee G,
Taylor JM, Macdonald J, Thomas D, Moskaluk C, Wang Y and Beer DG:
Gene expression signatures for predicting prognosis of squamous
cell and adenocarcinomas of the lung. Cancer Res. 66:7466–7472.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu CQ, Ding K, Strumpf D, Weir BA,
Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, et
al: Prognostic and predictive gene signature for adjuvant
chemotherapy in resected non-small-cell lung cancer. J Clin Oncol.
28:4417–4424. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee ES, Son DS, Kim SH, Lee J, Jo J, Han
J, Kim H, Lee HJ, Choi HY, Jung Y, et al: Prediction of
recurrence-free survival in postoperative non-small cell lung
cancer patients by using an integrated model of clinical
information and gene expression. Clin Cancer Res. 14:7397–7404.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hou J, Aerts J, den Hamer B, van Ijcken W,
den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens
JA, Hoogsteden HC, et al: Gene expression-based classification of
non-small cell lung carcinomas and survival prediction. PLoS One.
5:e103122010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bild AH, Yao G, Chang JT, Wang Q, Potti A,
Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al:
Oncogenic pathway signatures in human cancers as a guide to
targeted therapies. Nature. 439:353–357. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yamauchi M, Yamaguchi R, Nakata A, Kohno
T, Nagasaki M, Shimamura T, Imoto S, Saito A, Ueno K, Hatanaka Y,
et al: Epidermal growth factor receptor tyrosine kinase defines
critical prognostic genes of stage I lung adenocarcinoma. PLoS One.
7:e439232012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xie Y, Xiao G, Coombes KR, Behrens C,
Solis LM, Raso G, Girard L, Erickson HS, Roth J, Heymach JV, et al:
Robust gene expression signature from formalin-fixed
paraffin-embedded samples predicts prognosis of non-small-cell lung
cancer patients. Clin Cancer Res. 17:5705–5714. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Botling J, Edlund K, Lohr M, Hellwig B,
Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Pontén F, et
al: Biomarker discovery in non-small cell lung cancer: Integrating
gene expression profiling, meta-analysis, and tissue microarray
validation. Clin Cancer Res. 19:194–204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cancer Genome Atlas Research Network, .
Comprehensive genomic characterization of squamous cell lung
cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yan G, Du Q, Wei X, Miozzi J, Kang C, Wang
J, Han X, Pan J, Xie H, Chen J and Zhang W: Application of
real-time cell electronic analysis system in modern pharmaceutical
evaluation and analysis. Molecules. 23:32802018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang X, Guo H, Bao Y, Yu H, Xie D and
Wang X: Exosomal long non-coding RNA DLX6-AS1 as a potential
diagnostic biomarker for non-small cell lung cancer. Oncol Lett.
18:5197–5204. 2019.PubMed/NCBI
|
|
41
|
Guo Z, Zhang X, Zhu H, Zhong N, Luo X,
Zhang Y, Tu F, Zhong J, Wang X, He J and Huang L: TELO2 induced
progression of colorectal cancer by binding with RICTOR through
mTORC2. Oncol Rep. 45:523–534. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu J, Li J, Wang K, Liu H, Sun J, Zhao X,
Yu Y, Qiao Y, Wu Y, Zhang X, et al: Aberrantly high activation of a
FoxM1-STMN1 axis contributes to progression and tumorigenesis in
FoxM1-driven cancers. Signal Transduct Target Ther. 6:422021.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang X, Hu J, Zhong L, Wang N, Yang L,
Liu CC, Li H, Wang X, Zhou Y, Zhang Y, et al: Quercetin stabilizes
apolipoprotein E and reduces brain Aβ levels in amyloid model mice.
Neuropharmacology. 108:179–192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Stack EC, Wang C, Roman KA and Hoyt CC:
Multiplexed immunohistochemistry, imaging, and quantitation: A
review, with an assessment of Tyramide signal amplification,
multispectral imaging and multiplex analysis. Methods. 70:46–58.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liao H, Liang Y, Kang L, Xiao Y, Yu T and
Wan R: miR4543p inhibits nonsmall cell lung cancer cell
proliferation and metastasis by targeting TGFB2. Oncol Rep.
45:672021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kang J, Bai R, Liu K, Ji XP, Li Y and Han
JY: Identification of significantly different modules between
permanent and deciduous teeth by network and pathway analyses.
Genet Mol Res. 15:2016. View Article : Google Scholar
|
|
48
|
Perlikos F, Harrington KJ and Syrigos KN:
Key molecular mechanisms in lung cancer invasion and metastasis: A
comprehensive review. Crit Rev Oncol Hematol. 87:1–11. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mao M, Chen J, Li X and Wu Z: siRNA-TMEM98
inhibits the invasion and migration of lung cancer cells. Int J
Clin Exp Pathol. 8:15661–15669. 2015.PubMed/NCBI
|
|
50
|
Akkafa F, Koyuncu I, Temiz E, Dagli H,
Dilmec F and Akbas H: miRNA-mediated apoptosis activation through
TMEM 48 inhibition in A549 cell line. Biochem Biophys Res Commun.
503:323–329. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ombrato L and Malanchi I: The EMT
universe: Space between cancer cell dissemination and metastasis
initiation. Crit Rev Oncog. 19:349–361. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Son H and Moon A: Epithelial-mesenchymal
transition and cell invasion. Toxicol Res. 26:245–252. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hida Y and Hamada J: Differential
expressions of matrix metalloproteinases, a disintegrin and
metalloproteinases, and a disintegrin and metalloproteinases with
thrombospondin motifs and their endogenous inhibitors among
histologic subtypes of lung cancers. Anticancer Agents Med Chem.
12:744–752. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Engelman JA, Chen L, Tan X, Crosby K,
Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y,
et al: Effective use of PI3K and MEK inhibitors to treat mutant
Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med.
14:1351–1356. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Goodwin JM, Svensson RU, Lou HJ, Winslow
MM, Turk BE and Shaw RJ: An AMPK-independent signaling pathway
downstream of the LKB1 tumor suppressor controls Snail1 and
metastatic potential. Mol Cell. 55:436–450. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Qiao M, Sheng S and Pardee AB: Metastasis
and AKT activation. Cell Cycle. 7:2991–2996. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kim SO and Kim MR: [6]-Gingerol prevents
disassembly of cell junctions and activities of MMPs in invasive
human pancreas cancer cells through ERK/NF-κ B/Snail signal
transduction pathway. Evid Based Complement Alternat Med.
2013:7618522013. View Article : Google Scholar : PubMed/NCBI
|
